ライフサイエンスコーパス: GP

1 GP consultations with patients with suspected memory dis

2 GP from Reston ebolavirus, a nonpathogenic species in hu

3 GP of SM resulted in a significant increase in mean maxi

4 GP regression modeling of high-resolution time-series gr

5 GP signaling was impaired by altered paracrine signals f

6 GP was codon optimized and expressed either as a full-le

7 GP was inserted either preceding the N gene (pre-N) or b

8 GP-A82V was associated with increased mortality, consist

9 GP-alpha-syn or GP+RAP/alpha-syn immunizations resulted

10 GP-to-thalamus ratios differed significantly between the

11 GP:T and DN:P SI ratios were compared between groups by

12 GPs in the control group received no communication.

13 Letters were sent to 3227 GPs in the intervention group.

14 We isolated and characterized 349 GP-specific monoclonal antibodies (mAbs) from the periph

15 n control mean, 1.0183 +/- 0.01917; P = .37; GP-to-pulvinar ratio in case mean, 1.1335 +/- 0.04528; a

16 = -0.097, P = .65; SN: r = -0.194, P = .38; GP: r = -0.175, P = .41; pulvinar: r = -0.067, P = .75;

17 r = 0.106, P = .62; SN: r = -0.165, P = .45; GP: r = 0.111, P = .61; pulvinar: r = 0.173, P = .42.) C

18 lex with both an sGP-specific antibody and a GP/sGP cross-reactive antibody, permits us to unambiguou

19 et the CPRD threshold for data quality, in a GP practice defined by the CPRD as contributing up-to-st

20 s were then included as fixed effects into a GP model that also included the random effects of the wh

21 We aimed to assess whether a GP's personal letter, with an evidence-based leaflet abo

22 In accordance, GP-specific FcgammaRI reporter response and GP-specific

23 ances of C max and AUC were much lower after GP administration.

24 nd female mice were immunized with GP-alone, GP-alpha-syn (active humoral immunization), GP+RAP, or G

25 e high degree of sequence conservation among GP of Ebola viruses, it would be challenging to determin

26 ratio in case mean, 1.1335 +/- 0.04528; and GP-to-pulvinar ratio in control mean, 1.1141 +/- 0.07058

27 Conclusion Changes in SI of the DN and GP that are independent of the administration of GBCA oc

28 e higher in the ASD group than in the ID and GP groups.

29 uences of NP and VP40 (in phase 1) or NP and GP (in phase 2).

30 participants had positive results for NP and GP targets (samples obtained at 4.1 to 15.7 months after

31 p differences were found when DN-to-pons and GP-to-pulvinar ratios were compared (DN-to-pons ratio in

32 GP-specific FcgammaRI reporter response and GP-specific total IgG1 subclass correlated in the studie

33 f GP and sGP in complex with GP-specific and GP/sGP cross-reactive antibodies undergoing human clinic

34 DN/MCP, DN-to-pons, GP-to thalamus, and GP-to-cerebrospinal fluid ratios were measured and compa

35 nd emergency hospitalisations, and total and GP-referred specialist visits.

36 Although Ebola virus VP40 and GP both activate NF-kappaB independently of BST2, VP40 i

37 ions should be targeted at both patients and GPs.

38 With this system, we demonstrate that anti-GP-specific stimulation of the FcgammaRI reporter by sur

39 Naringin-carrying CHC-beta-GP-glycerol colloidal hydrogel can be used to inhibit in

40 Naringin-carrying CHC-beta-GP-glycerol hydrogel sites showed significantly reduced

41 hitosan (CHC), beta-glycerol phosphate (beta-GP), and glycerol.

42 arge portions of sequence are shared between GP and sGP, it has been hypothesized that sGP may potent

43 7 bound to the base region of membrane-bound GP.

44 en known for decades, the structure of brain GP (bGP) has remained elusive despite its critical role

45 tically, the maximal NF-kappaB activation by GP, VP40, and BST2 together requires the ectodomain cyst

46 r patients but did not do anything to change GP practice.

47 glycan cap, and inhibits binding of cleaved GP to its receptor.

48 s of GP values, generation of pseudo-colored GP maps, and spectral analysis, a key highlight of this

49 g a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes.

50 nulocyte progenitors (GPs); 2) tumor-derived GPs had an increased ability to form PMN-MDSCs; 3) tumor

51 ability to form PMN-MDSCs; 3) tumor-derived GPs shared gene expression patterns with IRF8(-/-) GPs,

52 f a fluorescence camera with gamma-detector (GP or GC) can be of value when a hybrid, radioactive and

53 ars, were examined for the presence of Ebola-GP specific IgG subclasses, and for their binding to Fcg

54 EBOV GP and RABV GP-specific antibody titers increased expone

55 inhibition of TLR4 signaling abolishes EBOV GP-mediated NF-kappaB activation.

56 g the Ebola virus surface glycoprotein (EBOV GP) are implicated in protection against lethal disease,

57 seudovirions bearing EBOV glycoprotein (EBOV GP/VSVDeltaG), we evaluated virus binding and entry into

58 our knowledge, unliganded structure of EBOV GP, and high-resolution complexes of GP with the antican

59 nferred correlated with the quantity of EBOV GP-specific Ig produced but not with the production of n

60 Our results show that EBOV GP/VSVDeltaG pseudovirions serve as a successful vaccina

61 pecific amino acid substitutions in the EBOV GP have increased tropism for human cells, while reducin

62 ught to shield conserved regions of the EBOV GP receptor-binding domain (RBD), thereby blocking epito

63 stics of the human antibody response to EBOV GP remain poorly understood.

64 Unmodified EBOV GP was packaged into the HPIV1 particle, and the TMCT mo

65 nt VSV where G protein is replaced with EBOV GP (rVSV-EBOV) is safe and highly efficacious.

66 e also tested whether VSVDeltaG bearing EBOV GPs that lack GP1 N-linked glycans provided effective im

67 The Ebola virus (EBOV) GP gene encodes two glycoproteins.

68 Eighty GP constructs were engineered and evaluated for GP1-GP2

69 On Sept 29, 2014, every GP in the feedback intervention group was sent a letter

70 virus (LCMV) glycoprotein (GP) and examined GP-specific CD4 T cell responses elicited by Ad5 vectors

71 r-field microscopy, where near-field excited GPs are detected thermoelectrically rather than opticall

72 titers and efficiently and stably expressed GP.

73 mmunogenic i.n. vaccine candidate expressing GP from the pre-N position.

74 Two doses of candidates expressing GP from the pre-N position elicited higher GP neutralizi

75 ized with two doses of the vector expressing GP from the pre-N position developed high titers of GP n

76 2.7 to 38.0 for NP and from 31.1 to 37.7 for GP.

77 eas no significant correlation was found for GP-to-thalamus ratios and number of gadoxetic acid admin

78 the trimeric interface and are important for GP-alphaDG interaction.

79 Providing French GPs caring for adults at average risk of CRC with a list

80 e assessed the role of attention in TAE from GPs.

81 ries of fatty acids and glycerophospholipid (GP) species between the normal and cancerous tissues.

82 membrane-anchored form of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

83 cine vector to express the EBOV glycoprotein GP.

84 s mediated by the EBOV envelope glycoprotein GP, which consists of subunits GP1 and GP2.

85 ll-like receptor 4 (TLR4) in a glycoprotein (GP)-dependent manner.

86 antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the

87 ils that target the Ebola coat glycoprotein (GP).

88 ence, such as A82V in the EBOV glycoprotein (GP) that occurred early in the 2013-16 epidemic, are sus

89 tein (VSVDeltaG) and bear EBOV glycoprotein (GP).

90 s mutation, Ebola virus (EBOV) glycoprotein (GP) mutant A82V, for its effect on viral infectivity.

91 choriomeningitis virus (LCMV) glycoprotein (GP) and examined GP-specific CD4 T cell responses elicit

92 Ectodomain shedding of glycoprotein (GP) Ibalpha is thought to mediate the clearance of activ

93 However, the EBOV and SUDV glycoprotein (GP) sequences are 45% divergent and thus antigenically d

94 ature triggered by the surface glycoprotein (GP), which can be inhibited by blocking TLR4 signaling.

95 cific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolav

96 monstrate that the Ebola virus glycoprotein (GP) acquired an A82V change during the West Africa epide

97 ion, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV antibodies were detected in 11% a

98 ix protein, VP40, and envelope glycoprotein, GP, each cooperate with BST2 to induce NF-kappaB activit

99 Old World arenavirus glycoproteins (GPs) mainly engage alpha-dystroglycan as a cell-surface

100 N terminus of the ebolavirus glycoproteins (GPs) and potently neutralizes Ebola, Sudan, Bundibugyo,

101 g GP from the pre-N position elicited higher GP neutralizing serum antibody titers than the N-P virus

102 ly available databases were used to identify GP practices whose prescribing rate for antibiotics was

103 GP-alpha-syn (active humoral immunization), GP+RAP, or GP+RAP/alpha-syn (combined active humoral and

104 association signals can effectively improve GP.

105 st visits per quarter and a 1.6% increase in GP-referred specialist visits (95% CI 1.2%-2.0%; p < 0.0

106 The role of mutations in GP and NP is not clear.

107 ressure to drive acquisition of mutations in GP that escape neutralization.

108 , with the plasma AUC of CTS, TSI and TSA in GP 5-184, 4-619 and 5-130 times higher than TD.

109 ndardised and sex-standardised rates were in GPs, with a rise of 12.36% per 10,000 person-years, comp

110 n vivo selectively constrained tumor-induced GP expansion.

111 Although infrared GPs have been visualized by scattering-type scanning nea

112 d methods to integrate results of GWASs into GP models in the context of multiple interconnected fami

113 Although studies have focused on intrinsic GP regulation, classic and recent experiments suggest th

114 were of greater value, while those involving GPs were more prevalent.

115 ses in [(11)C]-AIB uptake in the ipsilateral GP, which correlated with AIMs scores.

116 ared gene expression patterns with IRF8(-/-) GPs, suggesting that IRF8 loss underlies GP expansion; a

117 the trimeric, prefusion ectodomain of Lassa GP bound to a neutralizing antibody from a human survivo

118 to altered effector differentiation of LCMV GP-specific CD4 T cells compared to that during LCMV inf

119 munization with a DNA vector expressing LCMV-GP generated efficient CD4 Th1 responses.

120 mmunization with Ad5 vectors expressing LCMV-GP in mice.

121 exhibiting negligible binding to full-length GP, bound a proteolytically remodeled GP with picomolar

122 is also activated by AMP, contrary to liver GP, which is not.

123 Whereas the structures of muscle and liver GPs have been known for decades, the structure of brain

124 result from selective expansion of IRF8(lo) GPs, and that strategies targeting IRF8 expression may l

125 LUJV GP binds the N-terminal domain of NRP2, while CD63 stimu

126 RP2, while CD63 stimulates pH-activated LUJV GP-mediated membrane fusion.

127 t vesicular stomatitis virus containing LUJV GP as its sole attachment and fusion protein (VSV-LUJV),

128 P2) and tetraspanin CD63 as factors for LUJV GP-mediated infection.

129 However, the Lujo virus (LUJV) GP does not cluster with New or Old World arenaviruses.

130 ust growth advantage over wild-type rVSV-MAK-GP on Vero E6 cells.

131 g Ebola virus Makona variant GP1,2 (rVSV-MAK-GP) and observed emergence of a T544I mutation in the Ma

132 ion emerged within two passages when VSV-MAK-GP was grown on Vero E6, Vero, and BS-C-1 cells but not

133 venient and powerful technique for measuring GP and other membrane properties.

134 Summarily, tanshinones in micronized GP of SM had higher oral bioavailability and lower indiv

135 senting cell-targeting glucan microparticle (GP) vaccine delivery system.

136 nts suggest that local signals also modulate GP function.

137 a closer structural relationship with muscle GP, which is also activated by AMP, contrary to liver GP

138 Mutant GPs were used to generate a panel of pseudoviruses, whic

139 b-PAA27) polymer and graphene nanoplatelets (GP) suspension coated on filter paper to increase the se

140 We did a retrospective analysis of GP and nurse consultations of non-temporary patients reg

141 We used biochemical assays of GP function to show that A82V, as well as a polymorphism

142 and that this change altered the capacity of GP to be activated by host factors, enhancing infection

143 cts with the glycan cap and inner chalice of GP, remains associated after proteolytic removal of the

144 of EBOV GP, and high-resolution complexes of GP with the anticancer drug toremifene and the painkille

145 The number density of GP zones in the MPZ is lower than that in the matrix whi

146 such as the calculation of distributions of GP values, generation of pseudo-colored GP maps, and spe

147 Using a prime/boost strategy, high doses of GP/VSVDeltaG partially or fully denuded of N-linked glyc

148 The mean duration of GP surgery consultations increased by 6.7%, from 8.65 mi

149 We conclude that the observed effects of GP+RAP/alpha-syn immunization support the hypothesis tha

150 no iSNV enrichment within B-cell epitopes of GP has been observed.

151 ntry mediated by the primed (19-kDa) form of GP without impeding binding of the C-loop of NPC1, the e

152 that the heightened intrinsic infectivity of GP-A82V contributed to disease severity during the EVD e

153 n resonance kinetics showed higher levels of GP-binding antibodies after a single vaccination with 20

154 emotactic protein-1 compared with mothers of GP controls.

155 genicity but rather reduced the stability of GP expression during in vivo replication.

156 esent cryo-electron microscopy structures of GP and sGP in complex with GP-specific and GP/sGP cross-

157 a fluorescent protein tolerated swapping of GP with counterparts from heterologous filoviruses, allo

158 umans, showed a phenotype similar to that of GP from Zaire ebolavirus, a highly pathogenic species, i

159 ructure and epitope presentation to those of GP.

160 the pre-N position developed high titers of GP neutralizing serum antibodies.

161 ALR mutations can affect the biosynthesis of GPs.

162 Moreover, in the case of GPs, distraction is likely to interfere with the adaptat

163 ar dispersion resulting from the coupling of GPs with the metal gate below the graphene, and that pla

164 phene and 2DEGs has been elusive so far-only GPs with nearly free-space wavelengths have been observe

165 ted more efficiently with suitably optimized GP immunogens.

166 ompared with mice immunized with GP-alone or GP-alpha-syn, mice vaccinated with GP+RAP or GP+RAP/alph

167 dren with either ASD-noID, those with DD, or GP controls.

168 GP-alpha-syn, mice vaccinated with GP+RAP or GP+RAP/alpha-syn displayed increased numbers of CD25-, F

169 yn (active humoral immunization), GP+RAP, or GP+RAP/alpha-syn (combined active humoral and Treg) and

170 GP-alpha-syn or GP+RAP/alpha-syn immunizations resulted in a 30-45% redu

171 An oral dose of TD or GP of SM was administrated to subjects and blood samples

172 ears post infection; the prevalence of other GP-specific IgG subclasses was considerably reduced over

173 4.4%), Strep (84.1%), GN (93.6.%), and other-GP (52.8%).

174 (75.0%), Strep (8.0%), GN (95.7%), and other-GP (81.1%).

175 er coverage than CEF for CoNS, SA, and other-GP bacteria respectively (p<0.05, Fisher's exact), howev

176 vide better coverage for CoNS, SA, and other-GP, but not Strep.

177 eus (SA) (10.2%), other Gram-positive (other-GP) bacteria (7.4%) and Gram-negative (GN) bacteria (7.1

178 he dentate nucleus (DN) and globus pallidus (GP) in relation to the middle cerebellar peduncle (MCP),

179 , if not homologous, to the globus pallidus (GP) of mammals.

180 es was seen in the striatum/globus pallidus (GP) of the lesioned hemisphere.

181 In comparison, the globus pallidus (GP), a main striatal output nucleus, has received less f

182 al intensities (SIs) in the globus pallidus (GP), thalamus (T), dentate nucleus (DN), and pons (P) we

183 (SN), pulvinar thalami, and globus pallidus (GP).

184 deemed potentially eligible by participating GPs.

185 n-presenting cell-targeting glucan particle (GP) vaccine delivery system with encapsulated antigen (a

186 Glass patterns (GPs) consist of randomly distributed dot pairs (dipoles)

187 ticipants; 76 had generalized periodontitis (GP) and 65 had localized periodontitis (LP), whereas 79

188 tional neighbourhoods in genotype-phenotype (GP) maps are widely believed to be more likely to share

189 nd liver isoforms of glycogen phosphorylase (GP).

190 -induced type 1 diabetic (T1DM) guinea pigs (GPs).

191 through the excitation of graphene plasmons (GPs).

192 In the long bones, the growth plates (GPs) drive elongation by generating a scaffold progressi

193 aracterized by the generalized polarization (GP) parameter.

194 ipeptide repeat proteins (DPR: poly GA, poly GP, poly GR, poly PA, and poly PR), which aggregate into

195 together with other DPRs revealed that poly GP and poly PA are sequestered by poly GA, whereas poly

196 sed to compare SI and SI ratios (DN to pons, GP to thalamus) between case patients and control patien

197 DN/MCP, DN-to-pons, GP-to thalamus, and GP-to-cerebrospinal fluid ratios wer

198 ID (n = 181), as well as general population (GP) controls (n = 418).

199 velopmental Services and general population (GP) controls (n=418) from state birth certificates.

200 without ASD (N=188), and general population (GP) controls (N=428) using a bead-based multiplex techno

201 only mesenchyme cells surrounding postnatal GPs were killed, left bone growth was nevertheless reduc

202 estigate whether micronized granular powder (GP) of SM could improve the bioavailability of tanshinon

203 nts registered to the same general practice (GP) surgery.

204 for secondary care to general practitioner (GP) led Clinical Commissioning Groups (CCGs).

205 ials aimed at changing general practitioner (GP) practice have been unsuccessful.

206 ere recruited from 100 general practitioner (GP) practices in seven regions of the UK: Birmingham, Br

207 ine whether providing general practitioners (GPs) a list of patients who are nonadherent to CRC scree

208 clinical workload of general practitioners (GPs) and practice nurses in primary care in the UK.

209 General practitioners (GPs) report defensive antibiotic prescribing to mitigate

210 ate whether prompting general practitioners (GPs) to routinely assess and manage anxiety and depressi

211 ssociation study (GWAS), genomic prediction (GP) is typically based on models incorporating informati

212 ITOM) to either a gamma-ray detection probe (GP; VITOM-GP) or a portable gamma-camera (GC; Vitom GC),

213 We trained Gaussian process (GP) classification and regression models with expression

214 lation growth curves using Gaussian process (GP) regression.

215 ly defined IRF8(lo) granulocyte progenitors (GPs); 2) tumor-derived GPs had an increased ability to f

216 The template in control practices prompted GPs to ask the pain intensity question only.

217 eficial effect on pain outcomes of prompting GPs to routinely screen for and manage comorbid anxiety

218 virus adaptation to rodents in the proteins GP, NP, L, VP24 and VP35.

219 Providing GPs with generic reminders about regional rates of CRC s

220 EBOV GP and RABV GP-specific antibody titers increased exponentially duri

221 Among 1482 randomized GPs (mean age, 53.4 years; 576 women [38.9%]), 1446 part

222 Recently, GPs in a graphene/insulator/metal configuration have bee

223 ssibilities emerge from the strongly reduced GP wavelength, lambdap, compared with the photon wavelen

224 photocurrent images reveal strongly reduced GP wavelengths (lambdap approximately lambda0/66), a lin

225 length GP, bound a proteolytically remodeled GP with picomolar affinity, suggesting that engineered e

226 inactivated RESTV, or VLPs containing RESTV GP, indicating that RESTV GP does not trigger TLR4 signa

227 ed macrophages due to the inability of RESTV GP to stimulate TLR4.

228 s containing RESTV GP, indicating that RESTV GP does not trigger TLR4 signaling.

229 antigen-mismatched mouse model (C57BL/6 RIP-GP in C57BL/6) was used to evaluate the antigen-specific

230 for both reliable gene discovery and robust GP.

231 eral-Purpose Small-Angle Neutron Scattering (GP-SANS) instrument at Oak Ridge National Laboratory.

232 The template signposted GPs to follow National Institute for Health and Care Exc

233 This on-chip detection simplifies GP imaging as sophisticated s-SNOM detection schemes can

234 flux, increasing thereafter in Sham and T1DM GPs under both states 4 and 3 respiration with diabetic

235 whether empowering the public and targeting GPs would have resulted in a successful intervention.

236 This vaccine, collectively termed GP+RAP/alpha-syn, is capable of triggering neuroprotecti

237 We further demonstrate that GP-specific IgG1 is by far the seroprevalent subclass th

238 We found that GP-A82V had heightened ability to infect primate cells,

239 ing, cross-validation studies indicated that GP including the fixed effects of the most significantly

240 The GP:T ratios for the brain tumor groups were greater than

241 We apply the GP growth model and develop statistical tests to quantif

242 Environmental and staff screening at the GP surgery did not identify an ongoing source of infecti

243 care anxiety and depression screening by the GP, prompted by an automated electronic template compris

244 s recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the

245 e dysfunction occurred in 12 patients in the GP group and 4 control subjects (p = 0.038), and 6 pacem

246 and 6 pacemakers were implanted (all in the GP group; p = 0.013).

247 in the matrix while the average size of the GP zones in MPZ is coarser.

248 om the internal and external segments of the GP.

249 ization (10- to 30-cm range) of the SNs, the GP for providing convenient real-time acoustic feedback,

250 Together, these results demonstrate that the GP models are interpretable, recapitulating biological k

251 related MRSA isolates who were linked to the GP surgery, 2 of whom died with MRSA bacteremia.

252 e in the proportion of patients for whom the GP deactivated the template (33.6% [intervention] versus

253 were proportion of patients consulting their GP with suspected memory disorders and proportion of tho

254 ts with symptoms or a new diagnosis on their GP record) and cost per new COPD diagnosis.

255 ational neighbourhood of a genotype in these GP maps is much more likely to contain genotypes mapping

256 We use these GP models to identify ChRs that express and localize wel

257 participated; of the 33044 patients of these GPs (mean age, 59.7 years; 17949 women [54.3%]), follow-

258 over, the allosteric regulation of the three GP isozymes (muscle, liver, and brain) by metabolites an

259 that giving control of healthcare budgets to GP-led CCGs was not associated with a reduction in overa

260 ral congeners were found for ASD relative to GP (e.g., quartile 4 vs. 1, BDE-153: AOR=0.56, 95% CI: 0

261 hether the additional patients presenting to GPs had objective as well as subjective memory problems

262 osis resulted in more patients presenting to GPs with memory problems, but no diagnoses increase.

263 three-dimensional structure of the trimeric GP.

264 /-) GPs, suggesting that IRF8 loss underlies GP expansion; and 4) enforced IRF8 overexpression in viv

265 titers than the N-P viruses, and unmodified GP induced higher levels than its TMCT counterpart.

266 Thus, emergence of a virus GP with altered properties that can affect transmission

267 activation of NF-kappaB by BST2, Ebola virus GP does not inhibit NF-kappaB signaling even while it an

268 ither a gamma-ray detection probe (GP; VITOM-GP) or a portable gamma-camera (GC; Vitom GC), clip-on b

269 Using the VITOM-GP combination, we evaluated 9 SNs.

270 Results: Using the VITOM-GP combination, we evaluated 9 SNs.

271 Only VP24, GP and NP were consistently found mutated in rodent-adap

272 99 females with ASD, 77 with ID, and 73 with GP), estimates were consistent with overall analyses in

273 th ASD, and separately for ID, compared with GP controls, by quartiles of analyte concentrations in p

274 opy structures of GP and sGP in complex with GP-specific and GP/sGP cross-reactive antibodies undergo

275 Mice immunized with GP+RAP/alpha-syn further rescued neurons and reduced neu

276 Compared with mice immunized with GP-alone or GP-alpha-syn, mice vaccinated with GP+RAP or

277 tg) male and female mice were immunized with GP-alone, GP-alpha-syn (active humoral immunization), GP

278 Levels of TGF-beta1 were increased with GP+RAP/alpha-syn immunization, while levels of TNF-alpha

279 e how key cellular elements of patients with GP respond to Streptococcus pyogenes and whether this in

280 s were significantly higher in patients with GP than in patients with LP, whereas no difference was f

281 -alone or GP-alpha-syn, mice vaccinated with GP+RAP or GP+RAP/alpha-syn displayed increased numbers o

282 14, 2016, on the west coast of France, with GPs in 801 practices participating and involving adult p

283 s were no more effective than wild-type (WT) GP/VSVDeltaG and did not provide cross protection agains

284 the first in-depth characterization of ZEBOV-GP specific, circulating follicular T cells (cTfh).

285 The vaccine induced high GMTs of ZEBOV-GP-specific antibodies at day 28 in adolescents, 1,428 (

286 h 1 dose of 1 of 3 lots of rVSVDeltaG- ZEBOV-GP (2 x 107 plaque-forming units [pfu], n = 797; combine

287 , a single high-dose lot of rVSVDeltaG-ZEBOV-GP (1 x 108 pfu, n = 264; high-dose group), or placebo (

288 findings support the use of rVSVDeltaG-ZEBOV-GP vaccine in persons at risk for Ebola virus disease.

289 The rVSVDeltaG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2

290 rVSVDeltaG-ZEBOV-GP was generally well-tolerated, with increased rates of

291 elope glycoprotein vaccine (rVSVDeltaG-ZEBOV-GP).

292 roup (63.5%) and in those in the rVSVG-ZEBOV-GP group (79.5%) remained significantly greater than in

293 EBO-Z group, in 47 (9.4%) in the rVSVG-ZEBOV-GP group, and in 59 (11.8%) in the placebo group.

294 oup and in 83.7% of those in the rVSVG-ZEBOV-GP group, as compared with 2.8% of those in the placebo

295 group and 30.9% of those in the rVSVG-ZEBOV-GP group, as compared with 6.8% of those in the placebo

296 10(7), or 1 x 10(8) PFU doses of rVSVG-ZEBOV-GP or placebo.

297 10(5), or 3 x 10(6) PFU doses of rVSVG-ZEBOV-GP or placebo.

298 INTERPRETATION: rVSVG-ZEBOV-GP was well tolerated and stimulated a rapid onset of bi

299 s envelope glycoprotein vaccine (rVSVG-ZEBOV-GP) across a 6 log10 dose range in two sequential cohort

300 icular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in Liberia.